Last reviewed · How we verify
KSL 40 mg
At a glance
| Generic name | KSL 40 mg |
|---|---|
| Also known as | Ketoprofen lysine salt |
| Sponsor | Dompé Farmaceutici S.p.A |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dizziness
- Headache
Key clinical trials
- A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males (PHASE1)
- Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KSL 40 mg CI brief — competitive landscape report
- KSL 40 mg updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI